NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

NCT04158258

Active Not RecruitingN/A

Sponsor: Hoffmann-La Roche

Conditions: Breast Cancer

Interventions: Bevacizumab, Trastuzumab, Ado-trastuzumab emtamsine, Pertuzumab, Atezolizumab

Countries: Argentina, Brazil, Chile, Colombia, Cuba, Dominican Republic, Guatemala, Mexico

A Prospective, Multicenter, Non-Interventional Study of Primary Data Collection, Designed to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcomes in Patients with Breast Cancer in Latin America.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Histological confirmed newly diagnosed stage I to IV (recurrent or de novo) breast cancer no more than 12 months prior to site activation, although they can have received anti-cancer treatment during that time

Exclusion Criteria:

* Patients not receiving treatment for breast cancer with national approved drugs according to standard of care and in line with the current summary of product characteristics (SPC) /local labeling
* Patients not receiving the Roche studied medicinal product, but a biosimilar

Locations (30)

Buenos Aires, Argentina
Córdoba, Argentina
Córdoba, Argentina
Morón, Argentina
Rosario, Argentina
Rosario, Argentina
Fortaleza, Ceará, Brazil
Londrina, Paraná, Brazil
Volta Redonda, Rio de Janeiro, Brazil
Caxias do Sul, Rio Grande do Sul, Brazil
Porto Alegre, Rio Grande do Sul, Brazil
Rio de Janeiro, Brazil
São Paulo, Brazil
Santiago, Chile
Santiago, Chile
Temuco, Chile
Barranquilla, Colombia
Bogotá, Colombia
Cali, Colombia
Floridablanca, Colombia
La Habana, Cuba
Santo Domingo, Dominican Republic
Guatemala City, Guatemala
Mexico City, Mexico CITY (federal District), Mexico
Monterrey, Nuevo León, Mexico
Toluca, Mexico
Lima, Peru
Lima, Peru
Lima, Peru
Montevideo, Uruguay